New drug toxicities in the onco-nephrology world
New anticancer medications are rapidly entering the clinical arena offering patients with previously resistant cancers the promise of more effective therapies capable of extending their lives. However, adverse renal consequences develop in treated patients with underlying risk factors, requiring the...
Gespeichert in:
| Veröffentlicht in: | Kidney international 2015-05, Vol.87 (5), p.909-917 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 917 |
|---|---|
| container_issue | 5 |
| container_start_page | 909 |
| container_title | Kidney international |
| container_volume | 87 |
| creator | Perazella, Mark A. Izzedine, Hassan |
| description | New anticancer medications are rapidly entering the clinical arena offering patients with previously resistant cancers the promise of more effective therapies capable of extending their lives. However, adverse renal consequences develop in treated patients with underlying risk factors, requiring the nephrology community to be familiar with the nephrotoxic effects. The most common clinical nephrotoxic manifestations of these drugs include acute kidney injury, varying levels of proteinuria, hypertension, electrolyte disturbances, and at times chronic kidney disease. Thus, to practice competently in the 'onco-nephrology' arena, nephrologists will garner benefit from an update on older drugs with newly recognized nephrotoxic potential as well as newer agents, which may be associated with kidney injury. With that in mind, this brief update is meant to provide clinicians with the currently available evidence on the nephrotoxicity of a group of anticancer medications. |
| doi_str_mv | 10.1038/ki.2015.30 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1722174595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0085253815300806</els_id><sourcerecordid>1722174595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5060-a3fd4523572730d2fb29e17553d235afa0915ed982b5ccb4a9b70e3ceeb749973</originalsourceid><addsrcrecordid>eNpt0M1LwzAYBvAgipvTi3-AFLyI0JmPpmmOMvwC0YueQ5u83bJ1zUxa5_57MzY9iKfwhh8PDw9C5wSPCWbFzcKOKSZ8zPABGhJOWUoE54doiHHBU8pZMUAnIcxxvCXDx2hAeS6IyNkQ4RdYJ8b306RzX1bbzkJIbJt0M0hcq13awmrmXeOmm2TtfGNO0VFdNgHO9u8Ivd_fvU0e0-fXh6fJ7XOqOc5xWrLaZLEKF1QwbGhdUQnbWszEz7IusSQcjCxoxbWuslJWAgPTAJXIpBRshK52uSvvPnoInVraoKFpyhZcHxQRlBKRcckjvfxD5673bWynSC4kpYwURVTXO6W9C8FDrVbeLku_UQSr7Y5qYdV2R8VwxBf7yL5agvmlP8NFkO0AxA0-LXgVtIVWg7EedKeMs__lfgNUPHzk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1679223188</pqid></control><display><type>article</type><title>New drug toxicities in the onco-nephrology world</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Perazella, Mark A. ; Izzedine, Hassan</creator><creatorcontrib>Perazella, Mark A. ; Izzedine, Hassan</creatorcontrib><description>New anticancer medications are rapidly entering the clinical arena offering patients with previously resistant cancers the promise of more effective therapies capable of extending their lives. However, adverse renal consequences develop in treated patients with underlying risk factors, requiring the nephrology community to be familiar with the nephrotoxic effects. The most common clinical nephrotoxic manifestations of these drugs include acute kidney injury, varying levels of proteinuria, hypertension, electrolyte disturbances, and at times chronic kidney disease. Thus, to practice competently in the 'onco-nephrology' arena, nephrologists will garner benefit from an update on older drugs with newly recognized nephrotoxic potential as well as newer agents, which may be associated with kidney injury. With that in mind, this brief update is meant to provide clinicians with the currently available evidence on the nephrotoxicity of a group of anticancer medications.</description><identifier>ISSN: 0085-2538</identifier><identifier>EISSN: 1523-1755</identifier><identifier>DOI: 10.1038/ki.2015.30</identifier><identifier>PMID: 25671763</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>acute kidney injury ; Adenine Nucleotides - adverse effects ; Androgen Antagonists - adverse effects ; Angiogenesis Inhibitors - adverse effects ; Antibodies, Monoclonal - adverse effects ; Antineoplastic Agents - adverse effects ; Arabinonucleosides - adverse effects ; chemotherapy ; chronic kidney disease ; Humans ; Ipilimumab ; Kidney Diseases - chemically induced ; Oligopeptides - adverse effects ; onco-nephrology ; Pemetrexed - adverse effects ; Pyrazoles - adverse effects ; Pyridines - adverse effects</subject><ispartof>Kidney international, 2015-05, Vol.87 (5), p.909-917</ispartof><rights>2015 International Society of Nephrology</rights><rights>Copyright Nature Publishing Group May 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5060-a3fd4523572730d2fb29e17553d235afa0915ed982b5ccb4a9b70e3ceeb749973</citedby><cites>FETCH-LOGICAL-c5060-a3fd4523572730d2fb29e17553d235afa0915ed982b5ccb4a9b70e3ceeb749973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25671763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perazella, Mark A.</creatorcontrib><creatorcontrib>Izzedine, Hassan</creatorcontrib><title>New drug toxicities in the onco-nephrology world</title><title>Kidney international</title><addtitle>Kidney Int</addtitle><description>New anticancer medications are rapidly entering the clinical arena offering patients with previously resistant cancers the promise of more effective therapies capable of extending their lives. However, adverse renal consequences develop in treated patients with underlying risk factors, requiring the nephrology community to be familiar with the nephrotoxic effects. The most common clinical nephrotoxic manifestations of these drugs include acute kidney injury, varying levels of proteinuria, hypertension, electrolyte disturbances, and at times chronic kidney disease. Thus, to practice competently in the 'onco-nephrology' arena, nephrologists will garner benefit from an update on older drugs with newly recognized nephrotoxic potential as well as newer agents, which may be associated with kidney injury. With that in mind, this brief update is meant to provide clinicians with the currently available evidence on the nephrotoxicity of a group of anticancer medications.</description><subject>acute kidney injury</subject><subject>Adenine Nucleotides - adverse effects</subject><subject>Androgen Antagonists - adverse effects</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Arabinonucleosides - adverse effects</subject><subject>chemotherapy</subject><subject>chronic kidney disease</subject><subject>Humans</subject><subject>Ipilimumab</subject><subject>Kidney Diseases - chemically induced</subject><subject>Oligopeptides - adverse effects</subject><subject>onco-nephrology</subject><subject>Pemetrexed - adverse effects</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyridines - adverse effects</subject><issn>0085-2538</issn><issn>1523-1755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpt0M1LwzAYBvAgipvTi3-AFLyI0JmPpmmOMvwC0YueQ5u83bJ1zUxa5_57MzY9iKfwhh8PDw9C5wSPCWbFzcKOKSZ8zPABGhJOWUoE54doiHHBU8pZMUAnIcxxvCXDx2hAeS6IyNkQ4RdYJ8b306RzX1bbzkJIbJt0M0hcq13awmrmXeOmm2TtfGNO0VFdNgHO9u8Ivd_fvU0e0-fXh6fJ7XOqOc5xWrLaZLEKF1QwbGhdUQnbWszEz7IusSQcjCxoxbWuslJWAgPTAJXIpBRshK52uSvvPnoInVraoKFpyhZcHxQRlBKRcckjvfxD5673bWynSC4kpYwURVTXO6W9C8FDrVbeLku_UQSr7Y5qYdV2R8VwxBf7yL5agvmlP8NFkO0AxA0-LXgVtIVWg7EedKeMs__lfgNUPHzk</recordid><startdate>201505</startdate><enddate>201505</enddate><creator>Perazella, Mark A.</creator><creator>Izzedine, Hassan</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201505</creationdate><title>New drug toxicities in the onco-nephrology world</title><author>Perazella, Mark A. ; Izzedine, Hassan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5060-a3fd4523572730d2fb29e17553d235afa0915ed982b5ccb4a9b70e3ceeb749973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>acute kidney injury</topic><topic>Adenine Nucleotides - adverse effects</topic><topic>Androgen Antagonists - adverse effects</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Arabinonucleosides - adverse effects</topic><topic>chemotherapy</topic><topic>chronic kidney disease</topic><topic>Humans</topic><topic>Ipilimumab</topic><topic>Kidney Diseases - chemically induced</topic><topic>Oligopeptides - adverse effects</topic><topic>onco-nephrology</topic><topic>Pemetrexed - adverse effects</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyridines - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perazella, Mark A.</creatorcontrib><creatorcontrib>Izzedine, Hassan</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Kidney international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perazella, Mark A.</au><au>Izzedine, Hassan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New drug toxicities in the onco-nephrology world</atitle><jtitle>Kidney international</jtitle><addtitle>Kidney Int</addtitle><date>2015-05</date><risdate>2015</risdate><volume>87</volume><issue>5</issue><spage>909</spage><epage>917</epage><pages>909-917</pages><issn>0085-2538</issn><eissn>1523-1755</eissn><abstract>New anticancer medications are rapidly entering the clinical arena offering patients with previously resistant cancers the promise of more effective therapies capable of extending their lives. However, adverse renal consequences develop in treated patients with underlying risk factors, requiring the nephrology community to be familiar with the nephrotoxic effects. The most common clinical nephrotoxic manifestations of these drugs include acute kidney injury, varying levels of proteinuria, hypertension, electrolyte disturbances, and at times chronic kidney disease. Thus, to practice competently in the 'onco-nephrology' arena, nephrologists will garner benefit from an update on older drugs with newly recognized nephrotoxic potential as well as newer agents, which may be associated with kidney injury. With that in mind, this brief update is meant to provide clinicians with the currently available evidence on the nephrotoxicity of a group of anticancer medications.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25671763</pmid><doi>10.1038/ki.2015.30</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0085-2538 |
| ispartof | Kidney international, 2015-05, Vol.87 (5), p.909-917 |
| issn | 0085-2538 1523-1755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1722174595 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | acute kidney injury Adenine Nucleotides - adverse effects Androgen Antagonists - adverse effects Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - adverse effects Antineoplastic Agents - adverse effects Arabinonucleosides - adverse effects chemotherapy chronic kidney disease Humans Ipilimumab Kidney Diseases - chemically induced Oligopeptides - adverse effects onco-nephrology Pemetrexed - adverse effects Pyrazoles - adverse effects Pyridines - adverse effects |
| title | New drug toxicities in the onco-nephrology world |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A51%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20drug%20toxicities%20in%20the%20onco-nephrology%20world&rft.jtitle=Kidney%20international&rft.au=Perazella,%20Mark%20A.&rft.date=2015-05&rft.volume=87&rft.issue=5&rft.spage=909&rft.epage=917&rft.pages=909-917&rft.issn=0085-2538&rft.eissn=1523-1755&rft_id=info:doi/10.1038/ki.2015.30&rft_dat=%3Cproquest_cross%3E1722174595%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1679223188&rft_id=info:pmid/25671763&rft_els_id=S0085253815300806&rfr_iscdi=true |